20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
10X Genomics Inc (TXG) operates in the HEALTH INFORMATION SERVICES industry and is headquartered in Pleasanton, United States with about 1,178 employees. Its market capitalization is roughly $10 billion. In the fiscal year ended 2025-12-31, TXG reported $643M in revenue and ($44M) in net income.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Interactive charts & full statements → Open the TXG valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $617M | $643M | $611M | $619M | $516M | $490M | $299M | $246M | $146M | $71M |
| Gross Profit | $432M | $444M | $414M | $409M | $396M | $416M | $240M | $185M | $118M | $61M |
| Gross Margin % | 70.0% | 69.0% | 67.9% | 66.1% | 76.7% | 84.9% | 80.4% | 75.2% | 80.4% | 85.1% |
| Operating Income (EBIT) | ($88M) | ($111M) | ($195M) | ($265M) | ($168M) | ($53M) | ($85M) | ($29M) | ($111M) | ($18M) |
| Operating Margin % | -14.3% | -17.2% | -31.9% | -42.9% | -32.5% | -10.8% | -28.5% | -11.8% | -75.7% | -25.9% |
| Net Income | ($75M) | ($44M) | ($183M) | ($255M) | ($166M) | ($58M) | ($543M) | ($31M) | ($112M) | ($19M) |
| Net Margin % | -12.2% | -6.8% | -29.9% | -41.2% | -32.1% | -11.9% | -181.6% | -12.7% | -76.9% | -26.4% |
| EBITDA | $28M | $4M | ($134M) | ($205M) | ($128M) | ($25M) | ($514M) | ($21M) | ($106M) | ($14M) |
| Earnings Per Share (EPS) | $-0.59 | $-0.35 | $-1.52 | $-2.18 | $-1.46 | $-0.53 | $-5.37 | $-0.40 | $-8.40 | $-1.62 |
| Shares Outstanding (M) | 130M | 125M | 120M | 117M | 114M | 110M | 101M | 78M | 13M | 12M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $151M | $151M | $166M | $149M | $173M | $155M | $165M | $152M |
| Gross Profit | $112M | $106M | $113M | $100M | $125M | $105M | $111M | $106M |
| Gross Margin % | 74.5% | 70.4% | 68.1% | 67.3% | 72.3% | 68.1% | 67.2% | 70.2% |
| Operating Income (EBIT) | ($20M) | ($17M) | ($20M) | ($32M) | $30M | ($39M) | ($50M) | ($41M) |
| Operating Margin % | -13.0% | -11.3% | -11.8% | -21.6% | 17.4% | -25.4% | -30.2% | -27.4% |
| Net Income | ($18M) | ($13M) | ($16M) | ($27M) | $35M | ($34M) | ($49M) | ($36M) |
| Net Margin % | -11.9% | -8.9% | -9.8% | -18.4% | 20.0% | -22.2% | -29.7% | -23.6% |
| EBITDA | ($19M) | ($1M) | $64M | ($16M) | $47M | ($24M) | ($38M) | ($24M) |
| Earnings Per Share (EPS) | $-0.14 | $-0.10 | $-0.13 | $-0.22 | $0.28 | $-0.28 | $-0.40 | $-0.30 |
| Shares Outstanding (M) | 130M | 128M | 127M | 126M | 125M | 123M | 122M | 121M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $127M | $136M | $7M | ($15M) | ($34M) | ($21M) | ($218M) | $35M | ($76M) | ($11M) |
| Capital Expenditures (CapEx) | $6M | $6M | $12M | $50M | $132M | $101M | $38M | $43M | $7M | $4M |
| Free Cash Flow (FCF) | $121M | $130M | ($6M) | ($65M) | ($165M) | ($123M) | ($256M) | ($8M) | ($83M) | ($14M) |
| FCF Margin % | 19.7% | 20.2% | -0.9% | -10.5% | -32.0% | -25.0% | -85.8% | -3.3% | -56.8% | -20.3% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $17M | $26M | $41M | $43M | $18M | $34M | ($7M) | $22M |
| Capital Expenditures (CapEx) | $2M | $2M | $2M | $1M | $2M | $2M | $3M | $4M |
| Free Cash Flow (FCF) | $15M | $25M | $39M | $43M | $16M | $32M | ($9M) | $18M |
| FCF Margin % | 10.2% | 16.3% | 23.5% | 28.5% | 9.3% | 21.0% | -5.7% | 11.7% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.0B | $1.0B | $919M | $965M | $1.0B | $1.0B | $929M | $606M | $124M | $76M |
| Cash & Cash Equivalents | $503M | $474M | $344M | $359M | $220M | $587M | $664M | $424M | $65M | $48M |
| Total Liabilities | $205M | $245M | $209M | $224M | $223M | $201M | $190M | $186M | $344M | $188M |
| Total Debt (Short + Long-Term) | $12M | $11M | $9M | $12M | $9M | $5M | $6M | $30M | $30M | $11M |
| Total Shareholders' Equity | $826M | $796M | $710M | $741M | $806M | $818M | $739M | $420M | ($220M) | ($113M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TXG viewer.
About TickerBase · Data methodology & sources · Privacy · Terms